US 12,240,820 B2
Barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
Arie Lev Gruzman, Tzur Hadassah (IL); Paul Bradfield, Geneva (CH); Tamar Getter, Ashkelon (IL); Beat Imhof, Conches (CH); Thomas Matthes, Onex (CH); and Hanoch Senderowitz, Tel Aviv (IL)
Assigned to BAR-ILAN UNIVERSITY, Ramat Gan (IL); UNIVERSITY OF GENEVA, Geneva (CH); and GENEVA UNIVERSITY HOSPITALS, Geneva (CH)
Filed by BAR-ILAN UNIVERSITY, Ramat Gan (IL); UNIVERSITY OF GENEVA, Geneva (CH); and GENEVA UNIVERSITY HOSPITALS, Geneva (CH)
Filed on Jan. 20, 2023, as Appl. No. 18/099,611.
Application 18/099,611 is a division of application No. 17/957,549, filed on Sep. 30, 2022.
Application 17/957,549 is a division of application No. 16/642,496, granted, now 11,492,333, issued on Nov. 8, 2022, previously published as PCT/IL2018/050961, filed on Aug. 30, 2018.
Claims priority of provisional application 62/552,491, filed on Aug. 31, 2017.
Prior Publication US 2023/0150949 A1, May 18, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/62 (2006.01)
CPC C07D 239/62 (2013.01) 15 Claims
 
1. A compound of general Formula (Ib):

OG Complex Work Unit Chemistry
wherein
Z is absent; and
R5 is hydrogen, linear alkyl, branched alkyl, linear alkenyl or branched alkenyl, wherein each of the alkyl and the alkenyl may be unsubstituted or substituted with one, two, or three substituents selected from the group consisting of halo, nitro, cyano and amino; and stereoisomers, enantiomers and tautomers thereof, pharmaceutically acceptable salts thereof and mixtures thereof,
wherein the bonds to the barbituric acid moiety and to the linking group —O—CH2—are located meta to each other.